Arlington Partners’s Pfizer PFE Stock Holding History

Arlington Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,760	Closed	-$58.4K	–	353
2023 Q3	$58.4K	Sell	1,760 -8,323	-83%	-$294K	0.02%	132
2023 Q2	$370K	Sell	10,083 -3,228	-24%	-$126K	0.06%	101
2023 Q1	$543K	Buy	13,311 +4,825	+57%	+$208K	0.08%	76
2022 Q4	$435K	Sell	8,486 -897	-10%	-$43K	0.07%	68
2022 Q3	$411K	Sell	9,383 -124	-1%	-$6.03K	0.16%	65
2022 Q2	$498K	Hold	9,507	–	–	0.17%	66
2022 Q1	$492K	Buy	9,507 +124	+1%	+$6.43K	0.14%	70
2021 Q4	$554K	Buy	9,383 +1,170	+14%	+$58K	0.15%	64
2021 Q3	$353K	Buy	+8,213	New	+$364K	0.1%	75
2020 Q1	–	Sell	-1,413	Closed	-$53K	–	354
2019 Q4	$53K	Hold	1,413	–	–	0.03%	117
2019 Q3	$48K	Sell	1,413 -844	-37%	-$30.7K	0.03%	104
2019 Q2	$93K	Sell	2,257 -214	-9%	-$8.5K	0.04%	114
2019 Q1	$100K	Buy	2,471 +214	+9%	+$8.57K	0.07%	100
2018 Q4	$93K	Buy	2,257 +887	+65%	+$36.8K	0.06%	91
2018 Q3	$57K	Buy	1,370 +316	+30%	+$12.2K	0.04%	121
2018 Q2	$36K	Hold	1,054	–	–	0.03%	83
2018 Q1	$35K	Buy	+1,054	New	+$36.2K	0.03%	86

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Arlington Partners's PFE Position: Q4 2023 in Review

Arlington Partners sold out of Pfizer (PFE) in Q4 2023, closing a stake of 1,760 shares — an estimated $58.4K sold.

Arlington Partners first reported a position in PFE in Q1 2018 and held it in 17 quarters. The position peaked at $554K in Q4 2021. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

Arlington Partners reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
Arlington Partners sold 1,760 Pfizer shares in Q4 2023, an estimated $58.4K.
Arlington Partners first reported a position in Pfizer in Q1 2018 and held it in 17 quarters.
Arlington Partners's Pfizer position peaked at $554K in Q4 2021.
2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on Arlington Partners's 13F filing for Q4 2023, filed 24 Jan 2024.